Evaluation of iron dosing according to iron demand in hemodialysis patients treated with Darbepoetin alfa

Evaluation of iron dosing according to iron demand in hemodialysis patients treated with Darbepoetin alfa - Evaluation of iron dosing according to iron demand in hemodialysis patients treated with Darbepoetin alfa

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015869

Enrollment

100

Registered

2014-12-07

Start date

2014-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients treated with maintenance hemodialysis

Interventions

Iron supplementation after Darbepoetin alfa administration (Fesin 10mg x 3 in a week) No iron supplementation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with maintenance hemodialysis (2) Patients with renal anemia, who are treated with rHuEPO or iron

Exclusion criteria

Exclusion criteria: (1) Patients with chronic inflammation, malignant disorder, severe congestive heart failure, respiratory organs, and liver disorder (2) Patients who are receiving dialysis modalities other than hemodialysis

Design outcomes

Primary

Measure	Time frame
(1) Hemoglobin and erythropoiesis-related indexes (2)Blood chemical examination including iron-related, inflammation, nutrition indexes (3)Required dose of Darbepoetin alfa (4)Hemodynamic parameters	—

Countries

Japan

Contacts

Public ContactTadashi Kuji

Yokodai Central Clinic Director /Director of hemodialysis clinic

t.kuji@houshinkai.or.jp045-830-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026